Over the past decade, generics companies have saved the US healthcare system over $1.2 trillion. Globally, generics companies continue to reduce the ...

Although biosimilars have been widely adopted in highly regulated markets, including Europe, Canada, Australia, and Japan, the first biosimilar drug in ...

As large pharmaceutical companies increase their focus on orphan and specialty drugs, they are also seeking ways to reduce operating expenses and ...

The consumer products industry has always been marked by change, but it is even more pronounced now in the ‘age of the ...

In a letter this week to its suppliers, McKesson—the largest pharmaceutical distributor in the United States—addressed their expectations relating to ...

While increased healthcare spend will likely lead to higher revenues for manufacturers, life sciences companies will focus heavily on addressing ...

Launching a new, undifferentiated drug in a mature and highly regulated market can be challenging—even for an established organization. Facing the ...

The leadership team of a multinational healthcare company was dissatisfied with the organization’s ability to realize true value from its large scale. ...

The consumer products industry is a challenging and complex environment. The ultimate goal is profit and the ultimate plan to maximize ...

Seasonality is alive and well in the consumer products industry. Most relevant this week, with the 31st of October fast ...

As we continue our discussion about trade spend, we take a more in-depth look at the role of capital allocation in ...

As pharmaceutical companies introduce new therapies to the U.S. market, they respond to risk-sharing agreements (RSAs) from healthcare providers, which ...